Pancreatic Adenocarcinoma in Young Adults in a Moroccan Population

Raissouni, Soundouss; Rais, Ghizlane; Mrabti, Hind; Raissouni, F.; Mouzount, Houda; Aitelhaj, Meryem; Khoyaali, Siham; Mohtaram, Amina; Errihani, Hassan

doi:10.1007/s12029-012-9407-0

Cited by 13 publications

(12 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The main differences between the two PDAC groups were seen in demographic data. EOPC patients in our population were more frequently males, in agreement with previous studies [ 5 – 7 , 12 , 13 , 36 , 37 ]. In addition, our EOPC patients were less frequently of white British background and more commonly Asian or from ‘any other white background’.…”

Section: Discussionsupporting

confidence: 93%

“…Interestingly, the highest incidence of EOPC patients was reported in two independent studies conducted in North Africa, in Morocco [ 36 ] and Egypt [ 41 ]: 17% of PDAC patients were younger than 45 years in Morocco [ 36 ], and almost 25% in the East Nile Delta were under the age of 50 [ 41 ]. In both countries the male to female ratio was around 2:1, in accordance with other reports.…”

Section: Discussionmentioning

confidence: 99%

“…In both countries the male to female ratio was around 2:1, in accordance with other reports. Regarding smoking, in the Moroccan population only 12.5% of all EOPC patients were smokers [ 36 ]. In contrast, in Egypt smoking is highly prevalent (40% of the general population are smokers).…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Demographic, clinical, and pathological features of early onset pancreatic cancer patients

Ntala¹,

Debernardi²,

Feakins³

et al. 2018

BMC Gastroenterol

View full text Add to dashboard Cite

BackgroundEarly onset pancreatic cancer (EOPC), i.e. pancreatic ductal adenocarcinoma (PDAC) occurring in patients below 50 years of age, is rare and there is limited information regarding risk factors, molecular basis and outcome. This study aimed to determine the demographic and clinicopathological features and survival figures for EOPC.MethodsA retrospective analysis of patients treated at the Royal London Hospital for PDAC between September 2004 and September 2015 was performed. Data on demographics, risk factors, presentation, pathological features, treatment and survival outcome were compared in EOPC and older PDAC patients.ResultsOf 369 PDAC cases identified, 35 (9.5%) were EOPC. Compared to older patients, EOPC patients were more frequently male (71% vs 54%, p = 0.043) and less commonly of British origin (37% vs 70%, p = 0.002). There was no significant difference regarding the prevalence of any of the risk factors known to be associated with older PDAC patients. Fewer EOPC patients presented with resectable disease (23% vs 44%, p = 0.015) and more received adjuvant chemo/radiotherapy (60% vs 46%, p = 0.008). The overall median survival and stage specific survival did not differ significantly between the two groups, although a longer survival for localized disease was seen in EOPC patients (25 months (12.9–37, 95%CI) vs 13 months (10.5–15.5 95%CI) for older PDAC patients).ConclusionsThe EOPC patients had different demographics and were more likely than their older PDAC counterparts to be male. Typically they presented with more advanced disease, received more aggressive treatment, and had on overall similar survival outcome.

show abstract

Section: Discussionsupporting

confidence: 93%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Demographic, clinical, and pathological features of early onset pancreatic cancer patients

Ntala¹,

Debernardi²,

Feakins³

et al. 2018

BMC Gastroenterol

View full text Add to dashboard Cite

show abstract

“…[33][34][35][36] The results showed that the proportion of PDAC patients with diabetes mellitus was 23.9%, which is comparable to that reported by several authors. 1,22,28 Similar to the findings of other studies, the presenting symptoms for PDAC were dominated in our series by weight loss (68.6%), abdominal pain (64.2%) and jaundice (53.7%). 27,36,37 Present study showed that the tumor was located to the pancreatic head in the majority of cases (71.6%), This was in accordance with the results reported in the literature.…”

Section: Discussionsupporting

confidence: 90%

“…1 It is the 12 th most frequent cancer worldwide with 338 000 new cases and the 7 th most common cause of cancer death in the world with 331 000 deaths per year in both sexes in 2012. 2,3 Pancreatic ductal adenocarcinoma (PDAC) is the most common malignancy of the pancreas.…”

Section: Introductionmentioning

confidence: 99%

Pancreatic ductal adenocarcinoma in a Moroccan population: analysis of six years experience

et al. 2018

View full text Add to dashboard Cite

Background: Few studies have been done to investigate pancreatic cancer in Morocco. Therefore, the aim of our study was to describe the epidemiological, clinical and therapeutic features of pancreatic ductal adenocarcinoma in Moroccan population.Methods: Author retrospectively reviewed the medical data of pancreatic ductal adenocarcinoma patients presented to the Medical Oncology Department of the Military Hospital Moulay Ismail in Meknes, Morocco, from January 2011 to December 2016.Results: The study included 67 cases of pancreatic ductal adenocarcinoma. The mean age of patients was 61.24±10.35 years. Male/female ratio was 3.2/1. 20.9% of patients were cigarette smokers, 10.5% alcoholics. 23.9% diabetics, 3.0% with a positive family history of pancreatic cancer and 25.4% with a family history of diabetes mellitus. The main symptoms for consultation were weight loss (68.6%), abdominal pain (64.2%), jaundice (53.7%) and vomiting (25.4%). The tumour was located to the pancreatic head in 71.6% of cases. Stage IV disease was the most common stage representing 47.8% of patients. Biliary and duodenal stent placements were respectively performed in 10.4% and 3.0% of patients. 23.9% of patients underwent curative surgery, 7.5% had palliative surgery and 86.6% received chemotherapy. The median overall survival for the entire cohort was 9.3 months (95% CI 7.2-12.1 months) with a median follow-up of 9.7 months (2-63 months).Conclusions: The data on pancreatic ductal adenocarcinoma in Moroccan population are similar to the epidemiologic literature data. With multimodality treatments, the results in terms of survival benefit seem to be similar to those in Asian and Caucasian populations.

show abstract

Treatment patterns and survival in patients with early‐onset pancreatic cancer

Saadat

Chou

Gönen

et al. 2021

Cancer

View full text Add to dashboard Cite

Background Pancreatic cancer is uncommon in patients younger than 50 years, although its incidence is increasing. This study characterizes treatment utilization for early‐onset pancreatic cancer (EOPC) versus average‐age‐onset pancreatic cancer (AOPC) and identifies factors associated with failure to receive treatment. Methods The National Cancer Data Base (NCDB) was queried for patients with EOPC (age < 50 years) or AOPC (age ≥ 50 years) from 2004 to 2016. Multinomial regression was used to compare utilization (single modality vs multimodal treatment with or without surgery vs no treatment) between EOPC and AOPC. Kaplan‐Meier methods were used to estimate overall survival (OS). Results Of 248,634 patients, 15,710 (6.3%) had EOPC. There were more male patients (56% vs 50%), non‐White patients, and privately insured patients (61% vs 30%) with EOPC versus AOPC, without notable differences in clinical stage distribution. Patients with EOPC received more chemotherapy (38% vs 29%), surgery (9% vs 6.9%), chemoradiation (12% vs 9.2%), and multimodal treatment (21% vs 15%). The odds of receiving multimodal curative therapy were significantly higher for patients with EOPC versus patients with AOPC after adjustments for confounders (odds ratio, 3.89; 95% confidence interval [CI], 3.66‐4.15; P < .001). Nineteen percent of patients with EOPC, in contrast to 39% of patients with AOPC, received no treatment. Patients with AOPC more frequently declined chemotherapy (15% vs 9.5%). One‐year OS was higher for EOPC versus AOPC across each stage (0/I/II, 72% [95% CI, 71%‐74%] vs 53% [95% CI, 53%‐54%]; III, 48% [95% CI, 45%‐50%] vs 38% [95% CI, 37%‐38%]; IV, 25% [95% CI, 24%‐26%] vs 15% [95% CI, 15%‐15%]) and treated patients (0/I/II, 75% [95% CI, 74%‐77%] vs 64% [95% CI, 63%‐64%]; III, 51% [95% CI, 49%‐54%] vs 47% [95% CI, 47%‐48%]; IV, 29% [95% CI, 28%‐31%] vs 23% [95% CI, 23%‐24%]). Conclusions Patients with EOPC receive more oncologic therapy than patients with AOPC, although the intensity, type, and duration of chemotherapy are not available in the NCDB; however, 19% and 39%, respectively, receive no therapy. Underutilization may explain suboptimal oncologic outcomes. Efforts to improve access and treatment utilization in all age groups are warranted.

show abstract

Pancreatic Adenocarcinoma in Young Adults in a Moroccan Population

Cited by 13 publications

References 22 publications

Demographic, clinical, and pathological features of early onset pancreatic cancer patients

Demographic, clinical, and pathological features of early onset pancreatic cancer patients

Pancreatic ductal adenocarcinoma in a Moroccan population: analysis of six years experience

Treatment patterns and survival in patients with early‐onset pancreatic cancer

Contact Info

Product

Resources

About